News
New Clinical Trial to Evaluate Plixorafenib for BRAF V600E-mutated Neuroendocrine Carcinoma
A new global clinical trial is evaluating the investigational drug FORE8394 (plixorafenib) for treatment of neuroendocrine carcinomas with BRAF V600E-mutations. The phase 2 study aims
New Trial to Evaluate Combination of Fulvestrant and 177Lu-DOTATATE in Advanced Pancreatic Neuroendocrine Tumors
A new clinical trial at the University of Chicago Medicine is evaluating the combination of 177Lu-DOTATATE with fulvestrant in patients with advanced pancreatic neuroendocrine tumors
Understanding Ovarian Neuroendocrine Tumors: New Research Sheds Light on Diagnosis and Treatment
Neuroendocrine tumors (NETs) are complex cancers that can originate in various organs, including the ovaries. While primary ovarian NETs (PON) are uncommon, distinguishing them from
A Very Personal Perspective on the Value of Research
As the Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), I’ve dedicated my career to advancing science that gives patients and families more
A New Treatment Option for NET Patients
The U.S. Food and Drug Administration (FDA) has approved cabozantinib for the treatment of previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors
Early Positive Signs in CAR T Cell Therapy Trial
Chimeric Therapeutics is reporting early signs of efficacy in the world’s first clinical trial of CAR T cell therapy for neuroendocrine cancer. The first NET
NETRF Grantees Recognized for their Expertise at ENETS
Neuroendocrine cancer researchers from around the world gathered in Krakow, Poland for the 22nd Annual ENETS Conference in early March. The European Neuroendocrine Tumor Society
Advancing Neuroendocrine Tumor Research: The Urgent Need for Better Model Systems
Model systems—whether in vitro (cell lines), ex vivo (organoids), or in vivo (animal models)—are essential for understanding neuroendocrine cancer biology and testing new therapies. However,
Radiopharmaceutical ITM-11 Extends Progression-Free Survival in COMPETE Trial for GEP-NETs
The investigational therapy ITM-11 has shown promising results in the Phase 3 COMPETE trial for patients with inoperable, progressive Grade 1 and Grade 2 gastroenteropancreatic
FDA Grants Priority Review to Belzutifan as Pheo/Para Treatment
The U.S. Food and Drug Administration (FDA) has granted priority review to Merck’s application for WELIREG® (belzutifan) as a treatment for adult and pediatric patients